Publications
Detailed Information
Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Hoon-Gu | - |
dc.contributor.author | Kim, Joo-Hang | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Kim, Hoon-Kyo | - |
dc.contributor.author | Jang, Joung Soon | - |
dc.contributor.author | Kim, Bong-Seog | - |
dc.contributor.author | Kang, Jin-Hyoung | - |
dc.contributor.author | Lee, Kyung Flee | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Ryoo, Hun Mo | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Lee, Ki Hyeong | - |
dc.contributor.author | Kwon, Jung Hye | - |
dc.contributor.author | Choi, Jin-Hyuk | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T10:58:50Z | - |
dc.date.available | 2020-04-27T10:58:50Z | - |
dc.date.created | 2020-01-28 | - |
dc.date.created | 2020-01-28 | - |
dc.date.issued | 2019-01 | - |
dc.identifier.citation | Cancer Research and Treatment, Vol.51 No.1, pp.119-127 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.other | 89738 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165214 | - |
dc.description.abstract | Purpose This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC). Materials and Methods Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m(2) intravenously on days 1 and 8+cisplatin 70 mg/m(2) intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m(2) intravenously on days 1, 2, 3+cisplatin 70 mg/m(2) intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival. Results A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), <65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP. Conclusion The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC. | - |
dc.language | 영어 | - |
dc.publisher | 대한암학회 | - |
dc.title | Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 한서경 | - |
dc.identifier.doi | 10.4143/crt.2018.019 | - |
dc.citation.journaltitle | Cancer Research and Treatment | - |
dc.identifier.wosid | 000455439600013 | - |
dc.identifier.scopusid | 2-s2.0-85051509330 | - |
dc.citation.endpage | 127 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 119 | - |
dc.citation.volume | 51 | - |
dc.identifier.sci | 000455439600013 | - |
dc.identifier.kciid | ART002430542 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Hahn, Seokyung | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | ETOPOSIDE/CISPLATIN | - |
dc.subject.keywordPlus | PHARMACOGENETICS | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordAuthor | Etoposide | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | Small cell lung carcinoma | - |
dc.subject.keywordAuthor | Korean | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.